$ONCS News Article - OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO(TM) and KEYTRUDA in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
https://marketwirenews.com/news-releases/onco...99545.html